Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BioLineRx Ltd. (OTC: BLRX).

Full DD Report for BLRX

Recent News from (OTC: BLRX)

Wired News - vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes
Stock Monitor: BioLine Rx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you want access to this report all you need to do is sign up now by clicking the fol...
Source: ACCESSWIRE IA
Date: March, 27 2018 07:20
BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
TEL AVIV, Israel , March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office...
Source: PR Newswire
Date: March, 26 2018 07:00
Key events next week - healthcare (continued #1)
Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR ); Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS...
Source: SeekingAlpha
Date: March, 16 2018 10:26
BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference
TEL AVIV, Israel , March 14, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 28...
Source: PR Newswire
Date: March, 14 2018 07:00
The Speculative-Team: March 2018 Review
Background We recently introduced four teams: I(ncome)-Team : Pure income (lower risk)-oriented ideas. R(IC)-Team : Regulated Investment Corporations. G(rowth)-Team : Pure growth (higher risk) -oriented ideas. S(peculative)-Team : High-risk investment ideas. The main di...
Source: SeekingAlpha
Date: March, 13 2018 21:26
BioLineRx's (BLRX) CEO Philip Serlin on Q4 2017 Results - Earnings Call Transcript
Start Time: 10:00 End Time: 10:19 BioLineRx Ltd. (BLRX) Q4 2017 Earnings Conference Call March 06, 2018, 10:00 AM ET Executives Philip Serlin - CEO David Malek - Chief Business Officer Mali Zeevi - CFO Abi Vainstein-Haras - VP, Clinical and Medical Affairs Ella Sorani - V...
Source: SeekingAlpha
Date: March, 06 2018 12:58
BioLineRx Reports Year End 2017 Financial Results
TEL AVIV, Israel , March 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2017 . Highlights and achievements in 2017 and...
Source: PR Newswire
Date: March, 06 2018 07:00
BioLineRx to Report Annual 2017 Results on March 6, 2018
TEL AVIV, Israel, Feb. 27, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its audited annual financial results for the year ended December 31, 2017 ...
Source: PR Newswire
Date: February, 27 2018 07:00
Meet The Team: The King Is Dead. Long Live The King! - Part IV
Background The original A-Team was launched at the end of Q1/2016 , with ten names making its lineup: Main Street Capital (NYSE: MAIN ): Part I Ares Capital Corporation (NASDAQ: ARCC ): Part II Starwood Property Trust, Inc. (NYSE: STWD ): Part III New Residential Inv...
Source: SeekingAlpha
Date: February, 26 2018 05:58
The Market Has Bottomed Out: Here's What To Buy Now
The recent market correction is giving us a great buying opportunity. I think the market has bottomed out and that it will rebound soon. This market drop was sudden and rather violent based on how quickly the market dropped by about 10%. It appears that the market pullback got started over con...
Source: SeekingAlpha
Date: February, 14 2018 07:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-230.8420.85780.860.835396,636
2018-04-220.8420.85780.860.835396,636
2018-04-210.8420.85780.860.835396,636
2018-04-200.8420.85780.860.835396,636
2018-04-190.860.85990.860.835168,388

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report.


About BioLineRx Ltd. (OTC: BLRX)

Logo for BioLineRx Ltd. (OTC: BLRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (OTC: BLRX)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 16 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 26 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 06 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 06 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 12 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: January, 23 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: January, 23 2018

       

       


      Daily Technical Chart for (OTC: BLRX)

      Daily Technical Chart for (OTC: BLRX)


      Stay tuned for daily updates and more on (OTC: BLRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (OTC: BLRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BLRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BLRX and does not buy, sell, or trade any shares of BLRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

       

       

      Release this Report to Investors

      Via Email

      Via Text

      Important

      If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us